| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 6 | 2022 | 110 | 2.980 |
Why?
|
| Graft Rejection | 21 | 2022 | 458 | 2.680 |
Why?
|
| Liver Transplantation | 12 | 2023 | 400 | 2.160 |
Why?
|
| Kidney Transplantation | 20 | 2022 | 839 | 2.120 |
Why?
|
| Reperfusion Injury | 8 | 2022 | 320 | 2.110 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2021 | 199 | 1.400 |
Why?
|
| Arteriosclerosis | 5 | 2016 | 137 | 1.150 |
Why?
|
| Immunosuppressive Agents | 8 | 2022 | 514 | 1.090 |
Why?
|
| Heart Transplantation | 4 | 2021 | 328 | 0.980 |
Why?
|
| Mice, Inbred BALB C | 8 | 2021 | 532 | 0.900 |
Why?
|
| Transplantation, Homologous | 6 | 2016 | 242 | 0.880 |
Why?
|
| Endothelial Cells | 3 | 2022 | 384 | 0.820 |
Why?
|
| Adoptive Transfer | 5 | 2021 | 100 | 0.820 |
Why?
|
| Mitochondrial Dynamics | 1 | 2021 | 17 | 0.790 |
Why?
|
| Graft Survival | 10 | 2021 | 465 | 0.780 |
Why?
|
| Transplantation Tolerance | 1 | 2021 | 13 | 0.760 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 35 | 0.750 |
Why?
|
| CD40 Ligand | 1 | 2020 | 14 | 0.740 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 79 | 0.710 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 186 | 0.710 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 2791 | 0.700 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 163 | 0.670 |
Why?
|
| Biliary Atresia | 1 | 2018 | 7 | 0.630 |
Why?
|
| Situs Inversus | 1 | 2018 | 13 | 0.620 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 41 | 0.620 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 41 | 0.610 |
Why?
|
| Aorta, Abdominal | 3 | 2015 | 97 | 0.600 |
Why?
|
| Babesia | 1 | 2017 | 5 | 0.600 |
Why?
|
| Babesiosis | 1 | 2017 | 9 | 0.590 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 109 | 0.590 |
Why?
|
| Energy Metabolism | 1 | 2018 | 222 | 0.550 |
Why?
|
| Blood Transfusion | 2 | 2017 | 205 | 0.550 |
Why?
|
| Humans | 54 | 2023 | 68618 | 0.530 |
Why?
|
| Pancreas Transplantation | 3 | 2021 | 71 | 0.530 |
Why?
|
| Models, Animal | 2 | 2021 | 252 | 0.520 |
Why?
|
| Lung Transplantation | 3 | 2021 | 88 | 0.470 |
Why?
|
| Aorta, Thoracic | 1 | 2015 | 211 | 0.450 |
Why?
|
| Premedication | 1 | 2013 | 49 | 0.440 |
Why?
|
| Mitochondria | 1 | 2018 | 643 | 0.440 |
Why?
|
| Male | 34 | 2022 | 37321 | 0.420 |
Why?
|
| Complement Inactivating Agents | 3 | 2021 | 56 | 0.410 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 3 | 0.410 |
Why?
|
| Mice | 15 | 2021 | 8474 | 0.410 |
Why?
|
| Mucins | 1 | 2012 | 22 | 0.410 |
Why?
|
| Tissue and Organ Procurement | 3 | 2020 | 164 | 0.410 |
Why?
|
| Pancreatic Cyst | 1 | 2012 | 16 | 0.410 |
Why?
|
| Postoperative Complications | 6 | 2021 | 1615 | 0.410 |
Why?
|
| Animals | 22 | 2021 | 20881 | 0.400 |
Why?
|
| Vascularized Composite Allotransplantation | 2 | 2021 | 17 | 0.390 |
Why?
|
| Preoperative Care | 1 | 2013 | 275 | 0.390 |
Why?
|
| Mammary Arteries | 1 | 2010 | 18 | 0.360 |
Why?
|
| Retrospective Studies | 16 | 2023 | 7277 | 0.350 |
Why?
|
| Middle Aged | 24 | 2023 | 21147 | 0.350 |
Why?
|
| Glycolysis | 2 | 2021 | 79 | 0.350 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 124 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 332 | 0.320 |
Why?
|
| Patient Readmission | 5 | 2017 | 267 | 0.320 |
Why?
|
| Allografts | 2 | 2020 | 63 | 0.310 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 266 | 0.300 |
Why?
|
| Renal Insufficiency | 2 | 2020 | 121 | 0.290 |
Why?
|
| Patient Selection | 2 | 2020 | 592 | 0.270 |
Why?
|
| Induction Chemotherapy | 2 | 2017 | 39 | 0.270 |
Why?
|
| Immune Tolerance | 2 | 2022 | 114 | 0.260 |
Why?
|
| Adult | 21 | 2021 | 21403 | 0.260 |
Why?
|
| Female | 28 | 2021 | 38074 | 0.260 |
Why?
|
| Aged | 14 | 2021 | 14862 | 0.250 |
Why?
|
| Biliary Tract Diseases | 2 | 2015 | 50 | 0.240 |
Why?
|
| Kidney | 2 | 2020 | 945 | 0.240 |
Why?
|
| Tissue Donors | 4 | 2018 | 195 | 0.230 |
Why?
|
| Tacrolimus | 3 | 2020 | 127 | 0.230 |
Why?
|
| Radiation Pneumonitis | 1 | 2003 | 4 | 0.220 |
Why?
|
| Ischemia | 1 | 2004 | 229 | 0.220 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2023 | 8 | 0.220 |
Why?
|
| Rodentia | 2 | 2021 | 27 | 0.220 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2023 | 21 | 0.210 |
Why?
|
| Immunoglobulin G | 3 | 2020 | 481 | 0.210 |
Why?
|
| Young Adult | 9 | 2020 | 5717 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2021 | 376 | 0.210 |
Why?
|
| Pneumonectomy | 1 | 2003 | 79 | 0.210 |
Why?
|
| Connexins | 1 | 2022 | 35 | 0.210 |
Why?
|
| Medication Adherence | 2 | 2016 | 335 | 0.200 |
Why?
|
| Organ Preservation | 1 | 2022 | 69 | 0.200 |
Why?
|
| Blood Component Removal | 1 | 2022 | 19 | 0.200 |
Why?
|
| Brain Death | 2 | 2021 | 34 | 0.200 |
Why?
|
| eIF-2 Kinase | 1 | 2022 | 49 | 0.200 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 58 | 0.200 |
Why?
|
| P-Selectin | 1 | 2021 | 16 | 0.200 |
Why?
|
| Single-Chain Antibodies | 1 | 2021 | 15 | 0.200 |
Why?
|
| Immune Privilege | 1 | 2021 | 2 | 0.200 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 38 | 0.200 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2022 | 43 | 0.200 |
Why?
|
| Receptors, Complement 3b | 1 | 2021 | 35 | 0.200 |
Why?
|
| Hindlimb | 1 | 2021 | 38 | 0.200 |
Why?
|
| Donor Selection | 2 | 2020 | 29 | 0.200 |
Why?
|
| Nephrotic Syndrome | 1 | 2022 | 61 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 1 | 2023 | 157 | 0.190 |
Why?
|
| Interferon-gamma | 3 | 2013 | 241 | 0.190 |
Why?
|
| Carrier State | 1 | 2021 | 39 | 0.190 |
Why?
|
| Transplants | 1 | 2021 | 28 | 0.190 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 53 | 0.190 |
Why?
|
| Lung Injury | 1 | 2021 | 38 | 0.190 |
Why?
|
| Biological Evolution | 1 | 2021 | 86 | 0.190 |
Why?
|
| Cell Adhesion | 1 | 2021 | 324 | 0.180 |
Why?
|
| Acid Ceramidase | 1 | 2021 | 85 | 0.180 |
Why?
|
| Intestinal Perforation | 1 | 2020 | 35 | 0.180 |
Why?
|
| Complement Activation | 1 | 2021 | 145 | 0.180 |
Why?
|
| Immunologic Memory | 1 | 2020 | 75 | 0.180 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 47 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 110 | 0.170 |
Why?
|
| Heart Valves | 1 | 2021 | 171 | 0.170 |
Why?
|
| Antibodies | 2 | 2019 | 241 | 0.170 |
Why?
|
| Sphingosine | 1 | 2021 | 315 | 0.170 |
Why?
|
| Inflammation | 2 | 2018 | 1030 | 0.160 |
Why?
|
| Scleroderma, Systemic | 1 | 2023 | 446 | 0.160 |
Why?
|
| Liver | 1 | 2004 | 1118 | 0.160 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2010 | 32 | 0.160 |
Why?
|
| Hospital Costs | 2 | 2017 | 117 | 0.160 |
Why?
|
| Warm Ischemia | 1 | 2018 | 8 | 0.160 |
Why?
|
| Cold Ischemia | 1 | 2018 | 5 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2010 | 226 | 0.160 |
Why?
|
| Anastomosis, Surgical | 2 | 2015 | 104 | 0.160 |
Why?
|
| Aorta | 2 | 2012 | 316 | 0.160 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 71 | 0.160 |
Why?
|
| Risk Factors | 10 | 2019 | 5731 | 0.160 |
Why?
|
| Paracrine Communication | 1 | 2018 | 31 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4848 | 0.160 |
Why?
|
| Microdissection | 1 | 2018 | 15 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2021 | 337 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 581 | 0.150 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 1054 | 0.150 |
Why?
|
| Histone Deacetylase 1 | 1 | 2018 | 32 | 0.150 |
Why?
|
| Antiviral Agents | 2 | 2017 | 211 | 0.150 |
Why?
|
| Constriction, Pathologic | 2 | 2018 | 236 | 0.150 |
Why?
|
| Coculture Techniques | 1 | 2018 | 147 | 0.150 |
Why?
|
| Cholangiography | 1 | 2018 | 55 | 0.150 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2018 | 93 | 0.150 |
Why?
|
| Lung | 1 | 2003 | 849 | 0.150 |
Why?
|
| Ganciclovir | 1 | 2017 | 27 | 0.150 |
Why?
|
| Receptors, Complement | 1 | 2018 | 58 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2017 | 7029 | 0.150 |
Why?
|
| Bile Ducts | 1 | 2018 | 59 | 0.150 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2017 | 13 | 0.150 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2018 | 59 | 0.150 |
Why?
|
| Clindamycin | 1 | 2017 | 25 | 0.150 |
Why?
|
| Quinidine | 1 | 2017 | 15 | 0.150 |
Why?
|
| Cyclosporine | 1 | 2018 | 121 | 0.150 |
Why?
|
| Blood Donors | 1 | 2017 | 18 | 0.150 |
Why?
|
| Cholestasis | 1 | 2018 | 90 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2017 | 20 | 0.150 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2018 | 348 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2017 | 97 | 0.150 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 62 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2017 | 23 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 69 | 0.140 |
Why?
|
| Antimalarials | 1 | 2017 | 71 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 116 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2021 | 2689 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 529 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 848 | 0.140 |
Why?
|
| Health Care Rationing | 1 | 2017 | 32 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 244 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 397 | 0.140 |
Why?
|
| Tissue Engineering | 1 | 2018 | 212 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 298 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 42 | 0.130 |
Why?
|
| Wound Healing | 1 | 2018 | 260 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 148 | 0.130 |
Why?
|
| Infant | 3 | 2018 | 2891 | 0.130 |
Why?
|
| Monocytes | 2 | 2018 | 210 | 0.130 |
Why?
|
| Isografts | 1 | 2015 | 2 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 33 | 0.130 |
Why?
|
| Transplantation, Isogeneic | 1 | 2015 | 19 | 0.130 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.130 |
Why?
|
| Adolescent | 9 | 2021 | 8912 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3259 | 0.130 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2015 | 9 | 0.130 |
Why?
|
| Fatty Liver | 2 | 2007 | 97 | 0.130 |
Why?
|
| Phenotype | 1 | 2018 | 947 | 0.130 |
Why?
|
| Health Policy | 1 | 2017 | 221 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2001 | 778 | 0.120 |
Why?
|
| Cell Line | 1 | 2018 | 1752 | 0.120 |
Why?
|
| Death | 2 | 2020 | 38 | 0.120 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2014 | 24 | 0.120 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 2 | 2010 | 4 | 0.110 |
Why?
|
| Cytokines | 1 | 2018 | 866 | 0.110 |
Why?
|
| Liver Failure, Acute | 1 | 2014 | 49 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 378 | 0.110 |
Why?
|
| Liver Diseases | 1 | 2015 | 193 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2017 | 3705 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2014 | 249 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 807 | 0.110 |
Why?
|
| Transplant Recipients | 3 | 2020 | 109 | 0.100 |
Why?
|
| Antigens, Ly | 1 | 2012 | 14 | 0.100 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2013 | 101 | 0.100 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.100 |
Why?
|
| Mucin-2 | 1 | 2012 | 3 | 0.100 |
Why?
|
| Mucin 5AC | 1 | 2012 | 3 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1293 | 0.100 |
Why?
|
| Boston | 1 | 2012 | 35 | 0.100 |
Why?
|
| Algorithms | 4 | 2020 | 1196 | 0.100 |
Why?
|
| Mucin-1 | 1 | 2012 | 35 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1465 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 90 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2014 | 346 | 0.100 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 195 | 0.100 |
Why?
|
| Pancreatectomy | 1 | 2012 | 129 | 0.090 |
Why?
|
| Skin Transplantation | 1 | 2010 | 45 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.090 |
Why?
|
| Stents | 1 | 2015 | 657 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1085 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 34 | 0.090 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 50 | 0.090 |
Why?
|
| Cell Separation | 1 | 2010 | 132 | 0.090 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 2550 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1174 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 2324 | 0.080 |
Why?
|
| Depression | 1 | 2016 | 943 | 0.080 |
Why?
|
| Living Donors | 1 | 2011 | 160 | 0.080 |
Why?
|
| Length of Stay | 3 | 2017 | 780 | 0.080 |
Why?
|
| Prognosis | 3 | 2019 | 2093 | 0.080 |
Why?
|
| Hypertension | 2 | 2014 | 1535 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 567 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 365 | 0.070 |
Why?
|
| Isoantigens | 1 | 2007 | 26 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 80 | 0.070 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 597 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2023 | 2673 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2007 | 42 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 948 | 0.070 |
Why?
|
| Antilymphocyte Serum | 2 | 2017 | 52 | 0.070 |
Why?
|
| Waiting Lists | 2 | 2020 | 104 | 0.070 |
Why?
|
| Mice, Inbred CBA | 3 | 2012 | 107 | 0.070 |
Why?
|
| CD11b Antigen | 2 | 2018 | 47 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2007 | 114 | 0.060 |
Why?
|
| Child | 4 | 2022 | 6405 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 151 | 0.060 |
Why?
|
| Skin | 2 | 2023 | 451 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2004 | 14 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1342 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 351 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1753 | 0.060 |
Why?
|
| United States | 4 | 2017 | 7367 | 0.060 |
Why?
|
| Biopsy | 2 | 2015 | 540 | 0.060 |
Why?
|
| Cathepsin L | 1 | 2023 | 10 | 0.060 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 10 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 546 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2013 | 1692 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 125 | 0.050 |
Why?
|
| South Carolina | 2 | 2020 | 2752 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 4655 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1040 | 0.050 |
Why?
|
| Transplantation, Heterotopic | 1 | 2021 | 7 | 0.050 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.050 |
Why?
|
| Renal Veins | 1 | 2001 | 18 | 0.050 |
Why?
|
| Macrophages | 2 | 2018 | 647 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1603 | 0.050 |
Why?
|
| Varicose Veins | 1 | 2001 | 11 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2022 | 99 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 168 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 243 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 371 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 20 | 0.050 |
Why?
|
| Regeneration | 1 | 2021 | 105 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2003 | 800 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 170 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 384 | 0.040 |
Why?
|
| Rituximab | 1 | 2020 | 61 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 172 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 91 | 0.040 |
Why?
|
| Autophagy | 1 | 2022 | 208 | 0.040 |
Why?
|
| Calcinosis | 1 | 2001 | 241 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2021 | 249 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2003 | 300 | 0.040 |
Why?
|
| Lipoproteins, LDL | 1 | 2022 | 343 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2020 | 202 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 507 | 0.040 |
Why?
|
| Epitopes | 1 | 2019 | 146 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 377 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 2018 | 23 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 230 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2018 | 41 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.040 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2018 | 14 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2017 | 24 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 902 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2019 | 135 | 0.040 |
Why?
|
| Leukocytes | 1 | 2018 | 99 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2017 | 10 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2018 | 44 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 187 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 52 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 123 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 63 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 2007 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2018 | 164 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1174 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2019 | 434 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 328 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2015 | 3187 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2018 | 313 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 792 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1641 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 498 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 318 | 0.030 |
Why?
|
| Direct Service Costs | 1 | 2014 | 8 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 216 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2015 | 62 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2358 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 392 | 0.030 |
Why?
|
| Endoscopy | 1 | 2018 | 464 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 705 | 0.030 |
Why?
|
| Rabbits | 1 | 2015 | 509 | 0.030 |
Why?
|
| Drug Costs | 1 | 2014 | 87 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 733 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 1173 | 0.030 |
Why?
|
| Urban Population | 1 | 2015 | 255 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2013 | 122 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 186 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 155 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 202 | 0.030 |
Why?
|
| Rats | 1 | 2021 | 5300 | 0.030 |
Why?
|
| Heart | 1 | 2018 | 850 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 649 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2014 | 384 | 0.030 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2012 | 12 | 0.030 |
Why?
|
| Neointima | 1 | 2012 | 7 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2014 | 344 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 212 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2016 | 621 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1056 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2012 | 92 | 0.020 |
Why?
|
| Methylation | 1 | 2011 | 56 | 0.020 |
Why?
|
| Neutrophils | 1 | 2012 | 204 | 0.020 |
Why?
|
| Michigan | 1 | 2011 | 68 | 0.020 |
Why?
|
| Smoking | 1 | 2019 | 1452 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 2010 | 14 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 94 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 714 | 0.020 |
Why?
|
| Cholesterol | 1 | 2012 | 331 | 0.020 |
Why?
|
| Quinolones | 1 | 2011 | 60 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2010 | 82 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2011 | 169 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1864 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1619 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 489 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 682 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 700 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1034 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 978 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 502 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 2279 | 0.020 |
Why?
|
| Tissue Transplantation | 1 | 2007 | 9 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2007 | 19 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2007 | 45 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2007 | 42 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 49 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 1851 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1515 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2007 | 230 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 371 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2455 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2001 | 94 | 0.010 |
Why?
|